Detalles de la búsqueda
1.
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer
; 19(1): 620, 2019 06 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-31234810
2.
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
BMC Cancer
; 19(1): 517, 2019 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-31146717
3.
Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.
Gastric Cancer
; 22(4): 803-816, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30706247
4.
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.
Cancers (Basel)
; 14(11)2022 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35681574
5.
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.
Cancers (Basel)
; 13(19)2021 Sep 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34638369
Resultados
1 -
5
de 5
1
Próxima >
>>